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Pharmaceutical, Raritan, New Jersey, and 6Advanced Biologics LLC, Lambertville,
New Jersey
ABSTRACT
Background:
Changing etiologic patterns and the growing problem of antimicrobial resistance, particularly an increase in macrolide-resistant
pneumococcal
bacteremia, are
causing physicians to adopt new approaches to the treatment of community-acquired
pneumonia (CAP).
Objective: The relative efficacy and tolerability of levofloxacin monotherapy and azithromycin and ceftriaxone combination therapy were assessed in hospitalized adults with
moderate to severe CAP.
Methods: This Phase IV, multicenter, open-label, randomized trial compared 2 treatment regimens: (1) levofloxacin 500 mg PO or IV q24h, and (2) azithromycin 500 mg IV
q24h for ~2 days plus ceftriaxone 1 g IV q24h for 2 days, followed by an optional transition to azithromycin 500 mg PO q24h at the investigator’s discretion. The total duration
of therapy was to be a minimum of 10 days in both treatment groups. Ceftriaxone was
included in the initial azithromycin regimen to ensure coverage against pneumococcal
bacteremia.
Results: Of 236 patients in the intent-to-treat population, completion or withdrawal information was available for 110 patients in the levofloxacin group and 114 in the azithromycin group. Baseline demographic and disease characteristics were comparable between groups. At the end of treatment, the clinical success rate (cured + improved) in
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clinically evaluable patients was 94.1% in
the levofloxacin group and 92.3% in the
azithromycin group. The respective posttherapy microbiologic
eradication
rates
were 89.5% and 92.3%. Levofloxacin was
as well tolerated as azithromycin, with an
incidence of drug-related adverse events
(AEs) for all body systems of 5.3% and
9.3%, respectively. One patient receiving
levofloxacin
had a serious drug-related
AE, compared with 7 patients receiving
azithromycin.
Conclusions: In this study in hospitalized patients with moderate to severe CAP,
levofloxacin monotherapy was at least as
effective as a combination regimen of azithromycin and ceftriaxone in providing
coverage against the current causative
pathogens
in CAP. In addition,
levofloxacin was as well tolerated as the combination of azithromycin and ceftriaxone.
Key words: levofloxacin,
communityacquired pneumonia,
fluoroquinolones,
clinical trial. (Clin Thu. 2002;24: 12921308)

INTRODUCTION
Despite the availability
of effective antimicrobial agents, community-acquired
pneumonia (CAP) remains a potentially
life-threatening infection of the lower respiratory tract. The overall mortality rate
among patients hospitalized
with CAP
ranges from 5% to 25%, whereas the mortality rate in those with severe illness requiring treatment in the intensive care unit
ranges from 20% to 50%.lJ Streptococcus pneumoniae is the most common etiologic agent in hospitalized patients with
CAP, particularly those with severe disease. 3,4Pneumococcal bacteremia is a major complication
in hospitalized patients
with CAP, with an attributable mortality

rate ranging from 20% to 4 1% .5 The mortality rate in patients with severe CAP
who are bacteremic is -3 times that in patients with severe CAP who have negative blood cultures6
The significant risk of bacteremia in
patients with moderate to severe CAP supports selection of an antibiotic regimen
for initial in-hospital therapy that is active
against the main causative
pathogens
while achieving high drug concentrations
in plasma and lung tissue. Results of a
retrospective investigation in patients with
severe bacteremic pneumococcal
pneumonia suggest that monotherapy may produce suboptimal outcomes in this population.7 However, a retrospective review of
98 cases of CAP-associated pneumococcal bacteremia from prospective, randomized, controlled
clinical trials demonstrated a clinical success rate of 96.9%
and a microbiologic success rate of 95.9%
with levofloxacin 500 mg/d.8 In addition,
the Infectious Diseases Society of America (IDSA) recommends use of doxycycline, macrolides, or fluoroquinolones
for
the empiric treatment of most outpatient
cases of CAP and either a fluoroquinolone
alone or a beta-lactatieta-lactamase
inhibitor or extended-spectrum
cephalosporin combined with a macrolide for
most hospitalized patients with CAP in a
general medical ward?
This study compares the efficacy and
tolerability of 2 regimens -monotherapy
with levofloxacin and combination therapy with azithromycin and ceftriaxonethat meet IDSA criteria for the treatment
of CAP. Both are used for empiric treatment of moderate to severe CAP, although
recently there has been increased concern
about the association
of macrolides
with macrolide-resistant
pneumococcal
bacteremia.lO,ll

1293

CLINICAL THERAPEUTICS”

PATIENTS AND METHODS
Study Design
This was a Phase IV, multicenter, openlabel, randomized trial comparing the efficacy and tolerability
of levofloxacin
monotherapy and the combination of azithromycin and ceftriaxone in hospitalized
patients with moderate to severe CAP.

Znclusion and Exclusion

Criteria

Patients aged 218 years were eligible
for the study if they had a diagnosis of
moderate to severe pneumonia acquired
in the community or in a nursing home.
The diagnostic criteria included (1) characteristic clinical signs, including ~1 of
the following-fever
(oral temperature
>38”C), hypothermia
(oral temperature
<35.5”C), leukocytosis
(>lO,OOO white
blood cells/mm3), or bands >lO%; (2) radiologic evidence of pneumonia (an acute
infiltrate consistent with pneumonia
on
chest radiography); (3) collection of a mucopurulent sputum specimen for culture
and Gram’s staining within 24 hours before study drug administration;
and (4) a
Fine risk score12 of 71 to 130 (indicative
of moderate to severe disease and associated need for hospitalization) at study inclusion. Patients who had received previous antimicrobial therapy for any infection
were allowed to participate if the total duration of previous therapy was ~24 hours
or the patient had received >72 hours of
therapy but was classified as a treatment
failure.
Women of childbearing potential were
required to have had normal menstrual
flow in the month before study entry, to
have a negative result on serum pregnancy
testing (human chorionic gonadotropin l3
subunit) immediately before study entry
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or a negative urine pregnancy test (sensitive to 50 mIU/mL) if serum pregnancy
testing would delay treatment; and to have
been using hormonal contraception for 2 1
month before study entry, to have an intrauterine device, or to consent to using a
spermicide/barrier
method of contraception. Whichever method of contraception
was in use at the time of study entry was
to be continued
throughout
the study.
Women who had been postmenopausal for
81 year or had been rendered surgically
menopausal were also eligible.
Patients were excluded from study participation if they had an infection caused
by a pathogen known or suspected to be
resistant to any of the study drugs before
their admission to the study or if they had
experienced an allergic reaction or serious adverse reaction to levofloxacin,
azithromycin,
ceftriaxone,
or any other
member of the quinolone, macrolide, or
beta-lactam class of antimicrobial agents.
Patients were also ineligible if they had
been hospitalized within 2 weeks before
study entry (or within 1 month before
study entry if antimicrobial
therapy had
been administered during this time), or if
their life expectancy was ~72 hours.
Other exclusion criteria included creatinine clearance <20 mL/min (when only
serum creatinine data were available, the
Cockcroft-Gault equation was used to calculate creatinine clearance); empyema or
the presence of pleural fluid requiring an
indwelling chest tube; pneumonia due to
aspiration of gastric contents; HIV infection, with a CD4 cell count <200/cm3;
presence of any seizure disorder or a psychiatric condition requiring chronic use of
tranquilizers;
or presence of any disease
or disorder that could interfere with evaluation of the study treatments. Patients
who had received any experimental drug
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within 30 days before study entry were
also excluded.
All patients, or their legally authorized
representatives,
provided
written
informed consent.

Study Treatments
Randomization
was conducted according to a computer-generated
schedule prepared by Ortho-McNeil before initiation
of the study. Patients were randomized in
a 1: 1 ratio to 1 of 2 treatment groups: levofloxacin 500 mg PO or IV q24h, or azithromycin 500 mg IV q24h for 22 days plus
ceftriaxone 1 g IV q24h for 2 days, followed by an optional transition
to azithromycin
500 mg PO q24h at the investigator’s discretion. Ceftriaxone was
included in the initial azithromycin regimen to ensure coverage against pneumococcal bacteremia. The first dose of study
drug was administered as soon as admission procedures were completed and could
be given in the emergency department.
Thereafter, all doses were administered in
the morning. Oral levofloxacin
therapy
could be started at the time of study entry
or as soon as oral medication could be
tolerated. The duration of therapy was to
be a total of 10 days in both treatment
groups.
Levofloxacin
could be administered
without regard to meals, whereas oral azithromycin was taken 21 hour before or
>2 hours after a meal. In the levofloxacin
group, patients with a calculated creatinine clearance of 20 to 49 mL/min received an initial loading dose of levofloxacin 500 mg, followed by 250 mg
q24h. Patients with hepatic or renal impairment were administered azithromycin
and ceftriaxone with caution, as specified
in the respective package inserts.

The use of systemic corticosteroids was
contraindicated
during the study, unless
such therapy was already being received
for an unrelated medical condition. Patients requiring
antacid therapy were
strongly advised to use compounds containing calcium carbonate
rather than
magnesium-aluminum
hydroxide or sucralfate. If either of the latter was used, it
was to be taken >2 hours after study drug
administration.
Theophylline
levels were
closely monitored as clinically appropriate in both treatment groups, with dose
adjustment as necessary. Because concurrent use of macrolides or some quinolones
and warfarin or its derivatives has been
associated with increased anticoagulant
effects in clinical practice,13 the prothrombin time was closely monitored as clinically indicated in patients receiving warfarin or its derivatives. Given reports of
drug interactions between macrolides and
digoxin, ergotamine/dihydroergotamine,
triazolam,
carbamazepine,
terfenadine,
cyclosporine,
hexobarbital,
and phenytoin,14 patients receiving
any of these
drugs in combination
with azithromytin were monitored closely as clinically
indicated.

Study Evaluations
Patients were evaluated at the initial
(admission) visit, at which time a medical
history was obtained and a physical examination was performed. The severity of
pneumonia was assessed in terms of the
Fine risk score,‘* and posteroanterior and
lateral chest radiographs were obtained.
All patients were required to have a mucopurulent sputum specimen, which was
sent for Gram’s staining and culture. A
urine specimen was obtained for pregnancy testing, if applicable. Blood sam-
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ples were obtained for culture, serum pregnancy testing, complete
blood count
with differential, and measurement of arterial pH, blood urea nitrogen, sodium,
glucose, and arterial partial pressure of
oxygen. Any concomitant therapies were
recorded. Treatment with study drug was
then initiated.
Patients’ clinical status was evaluated
-72 hours after the start of treatment (days
3-5). Those whose condition had not stabilized or whose clinical signs/symptoms
had worsened after 72 hours were withdrawn from the study and were considered treatment failures. These patients
were switched to an appropriate
alternative therapy. Those whose condition
had stabilized but was not yet improved
could continue in the study at the investigator’s discretion. Patients whose admission organism was determined to be
resistant to study drug could also remain
in the study at the investigator’s discretion, provided they were clinically stable
or improving.
General, nondirected questioning was
used to elicit adverse events (AEs) occurring during treatment. Blinding to treatment assignment was not possible because
of the investigator’s
freedom to change
the route of administration or discontinue
ceftriaxone .
Between days 2 and 7 after the completion of therapy (or at early withdrawal), a
physical examination was performed, including recording of vital signs. Clinical
signs and symptoms were evaluated, and
the patient’s clinical response was assessed.
Posteroanterior
and lateral chest radiographs were obtained, as was a sputum
sample for Gram’s staining and culture, if
available. If the admission culture had been
positive or the patient was considered a
clinical failure, a blood sample was drawn
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for routine culture. Patients were questioned about any AEs that had occurred
during the study.

Ef$cacy and Safety Assessments
The primary efficacy variable was the
clinical response at the posttherapy (or
early-withdrawal)
assessment in clinically
evaluable patients (see Statistical Analysis section for definitions of study populations). Secondary efficacy variables included the posttherapy
microbiologic
response by infection; the posttherapy microbiologic response for each pathogen
isolated from an admission sputum culture; and the posttherapy microbiologic
response for blood pathogens isolated at
admission.
Clinical Ejkacy
Clinical efficacy was assessed by comparing the signs, symptoms, and radiologic
findings from the posttherapy (or earlywithdrawal) evaluation with those from
the admission evaluation. The following
definitions
were used to categorize the
clinical response: clinical cure-resolution of pretreatment
clinical signs and
symptoms (radiographic resolution not required) and no need for additional antimicrobial therapy; improved- significant improvement in clinical findings, but clinical
evidence of resolution incomplete during
therapy or at follow-up evaluation in a patient not requiring additional antimicrobial
therapy; failure-incomplete
response or
no apparent response to therapy, and need
for additional antimicrobial therapy; and
unevaluable-clinical
evaluation of cure,
improvement, or failure not possible because of inadequate follow-up data, use of
concomitant antimicrobial therapy, or protocol violation.
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Microbiologic

Eficacy

Microbiologic
response was assessed
by comparing the results of culture from
the posttherapy
(or early-withdrawal)
evaluation with those from the admission
evaluation. Based on the posttherapy (or
early-withdrawal)
culture results, each admission pathogen was assigned to 1 of the
following categories of microbiologic response: eradicated-negative
results on
culture in the absence
of additional
antimicrobial
therapy; presumed eradicated-no
respiratory specimen available
for culture and a clinical response of clinical cure or improved in the absence of
additional
antimicrobial
therapy; persisted-positive
posttherapy culture; presumed persistedin patients with a clinical response of clinical failure, no culture
or a negative test-of-cure culture while receiving additional antimicrobial
therapy;
and unable to evaluate-in
patients with
a clinical response of clinical cure, improved, or unable to evaluate, no test-ofcure culture due to loss to follow-up or
premature withdrawal, or a negative culture or no test-of-cure culture in the presence of additional antimicrobial
therapy.
Later reevaluation
identified any organisms that had been susceptible to study
treatment at admission but subsequently
acquired resistance.
At the posttherapy evaluation, each patient’s infection was assigned to 1 of the
following categories of microbiologic response based on the microbiologic
response of all pathogens isolated in that
patient at admission: eradicated/presumed
eradicated-all
pathogens isolated at admission were eradicated or presumed to
have been eradicated; mixed- 2 1 pathogen
isolated at admission was eradicated or
presumed to have been eradicated, while
others persisted or were presumed to have

persisted; persisted/presumed
persistedall pathogens isolated at admission persisted or were presumed to have persisted;
and unable to evaluate-a
judgment could
not be made.
Bacteremia was defined as 1 blood culture result positive for a pathogen at admission. In patients for whom no blood
culture was available at the posttherapy
evaluation,
the microbiologic
response
was classified as unknown if the clinical
response was cured or improved and as
presumedpersisted
if the clinical response
was failure. Superinfection
was defined
as the emergence or worsening of clinical
signs and symptoms requiring additional
antimicrobial
therapy when a pathogen
not isolated at admission
was isolated
from any site through the posttherapy
evaluation.

Safety
Tolerability was assessed based on findings of the physical examinations and laboratory tests performed during the study
and AEs reported by patients. Safety parameters were assessed separately for
oral and parenteral therapy. Treatmentemergent AEs were defined as new-onset
AEs or existing AEs whose severity or
frequency was exacerbated after administration of study drug, based on the investigator ‘s judgment.

Analysis Plan
Five populations were identified for the
purposes of analysis. The intent-to-treat
population included all randomized patients. The modified intent-to-treat population included those patients who had a
confirmed diagnosis of moderate to severe CAP and received sl dose of study
drug. The clinically evaluable population
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included patients who had clinical signs/
symptoms at admission and a chest radiograph consistent with acute pneumonia;
had a clinical response other than unable
to evaluate; had received
consecutive
doses of protocol-specified
drug on days
1 through 3 at minimum and ~7 doses
during the first 10 days (patients who discontinued study treatment as a result of
clinical failure after 72 hours of consecutive therapy were considered evaluable);
had received no concomitant or posttherapy treatment with another effective systemic antibiotic; and had a valid posttherapy evaluation.
The microbiologically
evaluable population included patients
who were evaluable for clinical efficacy;
had a specimen for culture obtained within
24 hours before starting study treatment;
had an admission pathogen recognized as
a potential cause of CAP; and had a valid
posttherapy evaluation, including a specimen for culture, if available. The safety
population included patients who took ~1
dose of study medication.
The primary efficacy variable was the
posttherapy clinical response (cured, improved, failed, or unable to evaluate) in
clinically evaluable patients. Clinical success was derived by combining the clinical
responses cured and improved. Clinical
success rates and by-patient microbiologic
eradication rates were analyzed by treatment group for each population.
To evaluate whether levofloxacin was
at least as effective as azithromycin,
2-sided 95% CIs (normal approximation to the binomial with a continuity
correction)
were computed around the
treatment
differences
(azithromycin
levofloxacin)
in posttherapy
response
rates.15 Statistical equivalence (ie, levofloxacin at least as effective as azithromycin) was considered to be demonstrated
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if the 95% CI crossed zero and the upper
limit was s15%.16
Posttherapy microbiologic
eradication
rates were summarized for microbiologitally evaluable patients in each treatment
group by pathogen
category
(grampositive vs gram-negative aerobes); pathogen and infection overall; and pathogen
within each culture category (respiratory,
blood, most prevalent pathogens). Twosided 95% CIs were computed around the
treatment
differences
(azithromycin
levofloxacin) in posttherapy microbiologic response rates. In microbiologically
evaluable patients, a cross-tabulation
of
by-patient microbiologic response versus
clinical response was performed. Pathogens were classified by those isolated
from respiratory cultures and those isolated from blood cultures. In clinically
evaluable patients, posttherapy clinical response rates by pathogen within each culture category were summarized
for the
most prevalent pathogens (those isolated
at admission from ~5 patients in each
treatment group).
Approximately
198 patients were to be
randomized to treatment to provide 148
clinically evaluable patients, with a minimum of 74 patients in each treatment
group. This would provide 80% power to
test the null hypothesis, assuming an 88%
clinical success rate in each of the treatment groups, at a significance
level of
0.025.

RESULTS
Between December 15,1997, and June 7,
1999, 236 patients were randomized to
treatment and received 1 of the 2 study
regimens (Table I). These patients composed the intent-to-treat
population. The
levofloxacin group received IV treatment
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Table I. Patient disposition,

intent-to-treat

(ITT) population

(all randomized

patients).

No. (%)

Levofloxacin
ITT population
No. with completion/withdrawal
Lost to follow-up
Total completing
Total withdrawals
Reason for withdrawal
Adverse event
Clinical failure
Negative radiographic
Personal reason
No study drug taken
Other

115
110
5

121
114
I

92 (83.6)

86 (75.4)

23 (20.9)

35 (30.7)

information+

study

findings

Modified ITT populationt

Comparator Regimen*

5
4
3
2
2
7

(4.5)
(3.6)
(2.7)
(1.8)
(1.8)
(6.4)

5
6
4
2
3
15

(4.4)
(5.3)
(3.5)
(1.8)
(2.6)
(13.2)

106

105

Clinically evaluable population

85

78

Microbiologically

36

35

evaluable population

*Comparator regimen consisted of azithromycin 500 mg IV q24h for r2 days plus ceftriaxone 1 g IV q24h for
2 days, followed by an optional switch to azithromycin 500 mg PO q24h at the investigator’s discretion.
+Percentages are based on number of patients with completion/withdrawal
information.
‘Patients in ITT population with a confirmed diagnosis of moderate to severe community-acquired
pneumonia
who took rl dose of study drug.

for a mean of 3.67 days, and the azithromycin group received IV treatment for a
mean of 3.83 days (plus a mean 2.36 days
of IV ceftriaxone).
Five patients in the
levofloxacin group and 7 in the azithromycin group were lost to follow-up (eg,
were transferred
to another facility).
Completion/withdrawal
data were therefore available for 110 patients in the levofloxacin group and 114 in the azithromytin group. Twenty-three (20.9%) patients
in the levofloxacin group withdrew prematurely: 5 (4.5%) due to AEs, 4 (3.6%)
for clinical failure, 3 (2.7%) due to a negative radiograph, and 11 (10.0%) for per-

sonal or other reasons or because no study
drug was taken. Thirty-five (30.7%) patients in the azithromycin group withdrew
prematurely:
5 (4.4%) due to AEs, 6
(5.3%) for clinical failure, 4 (3.5%) due
to a negative radiograph, and 20 (17.5%)
for personal or other reasons or because
no study drug was taken. A total of 211
patients were included in the modified
intent-to-treat
population,
163 of whom
were clinically evaluable and 7 1 of whom
were microbiologically
evaluable.
Baseline demographic and disease characteristics were similar in clinically evaluable patients in the 2 treatment groups
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(Table II). The mean duration of pneumonia at baseline was 7.3 days, and the mean
Fine risk score was 93.4. Somewhat less
than one third (47/163) of patients were
current smokers, with a history of 68.9
pack years (data not shown).
Table III lists the clinical response rates
at the posttherapy (or early-withdrawal)

Table

II. Baseline demographic
patients .*

and disease

Levofloxacin

evaluation.
In clinically
evaluable
patients, the clinical success rate was 94.1%
in the levofloxacin group and 92.3% in
the azithromycin group (95% CI, -10.20
to 6.58). The clinical success rates in the
modified intent-to-treat population were a
respective 89.6% and 85.7% (95% CI,
-13.24 to 5.43). In microbiologically

characteristics

Comparator

of clinically

Regimen+

evaluable

Total

(n = 85)

(n = 78)

(N = 163)

Male

56 (65.9)

60 (76.9)

116 (71.2)

Female

29 (34.1)

18 (23.1)

47 (28.8)

67.8 f 13.11

67.3 + 13.17

67.6 + 13.10

Sex, no. (%)

Age, Y
Mean * SD
Range
Race,

29-94

41-90

no. (%)

White

68 (80.0)

56 (7 1.8)

Black

8 (9.4)

11 (14.1)

Asian

l(l.2)

Other

8 (9.4)

Body

weight,

Mean

Data missing,
Duration

171.9246.85
no. (%)

of illness,

19 (11.7)

0 (0.0)

1 (0.6)

11 (14.1)

19 (11.7)

160.6 f 41.31

166.7 + 44.58

95-355

70-273

70-355

5 (5.9)

9 (11.5)

14 (8.6)

7.3 + 6.26

7.2 f 7.23

7.3 + 6.72

l-32

l-47

l-47

l(l.2)

I (1.3)

2 (1.2)

91.3 zt 16.93

95.8 + 20.24

93.4 f 18.67

61-136

62-149

61-149

d

+ SD

Range
Data missing,

124 (76.1)

lb

f SD

Range

Mean

29-94

no. (%)

Fine risk scorei
Mean
Range

+ SD

*Patients with clinical signs/symptoms
and a chest radiograph consistent with acute pneumonia at admission
who had a clinical response other than unable fo evalua?e, had received consecutive doses of study drug on
days 1 through 3 and k7 doses in the first 10 days and no concomitant or posttherapy treatment with another
systemic antibiotic, and had a valid posttherapy evaluation.
tcomparator
regimen consisted of azithromycin 500 mg IV q24h for 22 days plus ceftriaxone 1 g IV q24h for
2 days, followed by an optional switch to azithromycin 500 mg PO q24h at the investigator’s discretion.
“A score of 71 to 130 is indicative of moderate to severe disease and associated need for hospitalization.
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Table III. Clinical response rates at the end of therapy.
Clinical Success,* no./N (%)
Subgroup

Levofloxacin

Intent-to-treat”
Modified intent-to-treat”
Clinically evaluable
Microbiologically evaluable

100/115
95/106
80/85
33/36

(87.0)
(89.6)
(94.1)
(91.7)

Comparator
97/121
90/105
72/78
33/35

Regimen+
(80.2)
(85.7)
(92.3)
(94.3)

95% c1*
-16.63
-13.24
-10.20
-10.67

to
to
to
to

3.04
5.43
6.58
15.91

*Clinical success = cure + improved.
+Comparator regimen consisted of azithromycin 500 mg IV q24h for r2 days plus ceftriaxone 1 g IV q24h for
2 days, followed by an optional switch to azithromycin 500 mg PO q24h at the investigator’s discretion.
*Two-sided 95% CI around the difference (comparator regimen - levofloxacin) in clinical success rates.
“Five patients in the levofloxacin group and 10 patients in the comparator group were considered clinical successes based solely on the evaluation conducted during therapy.
“Four patients in the levofloxacin group and 2 patients in the comparator group were considered clinical successes based solely on the evaluation conducted during therapy.

evaluable patients, the clinical success
rates were 91.7% and 94.3%, respectively
(95% CI, -10.67 to 15.91). Twelve patients in the levofloxacin group received
only oral levofloxacin therapy. The clinical success rate in these patients was
100%.
Clinical and microbiologic
response
rates were comparable within each treatment group (Table IV). All 33 microbiologically evaluable patients in the levofloxacin group who had a posttherapy
microbiologic response of eradicated had
a clinical response of cure or improved.
The 3 patients with a microbiologic
response of persisted were classified as
clinical failures. Of 3.5 patients in the
azithromycin
group who were microbiologically evaluable and had a posttherapy microbiologic
response
of eradicated, 33 (94.3%) had a clinical response
of cure or improved. The remaining
2
(5.7%) patients were considered clinical
failures.

S pneumoniae was isolated from sputum cultures obtained from 29 patients,
14 in the levofloxacin group and 15 in the
azithromycin
group. Haemophilus injluenzae was isolated from sputum cultures
obtained from 22 patients, 9 in the levofloxacin group and 13 in the azithromycin
group. The eradication rate for S pneumoniae in sputum cultures was 100% in both
the levofloxacin and azithromycin groups
(95% CI, -3.57 to 3.57); the eradication
rate for H injkenzae
was also 100% in
both groups (95% CI, -5.56 to 5.56).
S pneumoniae
was also isolated from
blood cultures obtained from 5 patients in
the clinically evaluable population, 3 in
the levofloxacin group and 2 in the azithromycin group. The eradication rate for
Spneumoniae in blood cultures was 100%
in both the levofloxacin and azithromycin
groups. All other pathogens
isolated
from respiratory
or blood cultures occurred in <5 patients in either treatment
group.
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Table IV. Comparison

of microbiologic

and clinical response at the end of therapy.

A. Levofloxacin (n = 36)
Clinical Response, No. (%)
Cure
Microbiologic response
Eradicated*
Persisted+
Total

29 (87.9)
0 (0)
29 (80.6)

Improved

Failure

Unable to Evaluate

Total

4 (12.1)
0 (0)
4 (11.1)

0 (0)
3 (100)
3 (8.3)

0 (0)
0 (0)
0 (0)

33
3
36

Failure

Unable to Evaluate

Total

0 (0)
0 (0)
0 (0)

35
0
35

B. Comparator Regimens (n = 35)

Clinical Response, No. (%)

Microbiologic
Eradicated*
Persisted+
Total

Cure

Improved

23 (65.7)

10 (28.6)

2 (5.7)

0 (0)
23 (65.7)

0 (0)
10 (28.6)

0 (0)
2 (5.7)

response

*Microbiologic eradication rates are per patient (ie, they reflect eradication of all pathogens isolated at admission from a particular patient).
+Persisted rates include the infection categories persisted, mixed, and unable to evaluate.
*Comparator regimen consisted of azithromycin 500 mg IV q24h for 22 days plus ceftriaxone 1 g IV q24h for
2 days, followed by an optional switch to azithromycin 500 mg PO q24h at the investigator’s discretion.

Table V presents the susceptibilities to
the study drugs of the 122 bacterial isolates cultured at admission. The susceptibilities of 18 isolates were unknown. Of
104 admission isolates for which susceptibilities were determined, 103 were susceptible to levofloxacin, 95 to azithromycin,
and 100 to ceftriaxone. One isolate was intermediately susceptible to levofloxacin, 1
was intermediately susceptible to azithromycin, and 3 were intermediately susceptible to ceftriaxone. None of the 104 isolates were resistant
to levofloxacin,
whereas 8 were resistant to azithromycin
and 1 was resistant to ceftriaxone.
The cross-susceptibilities
of admission
pathogens to levofloxacin and azithromy-
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tin are shown in Table VI. Of 103 isolates
that were susceptible to levofloxacin, 95
were also susceptible to azithromycin,
1
was intermediately susceptible, and 7 were
resistant. The 1 isolate that was intermediately susceptible to levofloxacin was resistant to azithromycin.
Table VII shows
the cross-susceptibilities
of admission
pathogens to levofloxacin and ceftriaxone.
Of 103 isolates that were susceptible to
levofloxacin, 99 were also susceptible to
ceftriaxone, 3 were intermediately susceptible, and 1 was resistant. The 1 isolate that
was intermediately
susceptible to levofloxacin was susceptible to ceftriaxone.
The clinical characteristics of the 5 patients classified as treatment failures are
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Table V. Susceptibility

to study drugs of admission

pathogens.
No. of Isolates

Levofloxacin*
Susceptible
Intermediately susceptible
Resistant
Unknown
Total

Azithromycin*

103
1
0
18
122

9.5
1
8
18
122

*Twopatients in the levofloxacin

group and 3 patients in the comparator
but did not receive study medication.

Table VI. Cross-susceptibility

to levofloxacin

Ceftriaxone
100
3
I
18
122

group were randomized

and azithromycin

of admission

to treatment

pathogens.

Azithromycin,* No. of Isolates

Levofloxacin,” no. of isolates
Susceptible
Intermediately susceptible
Resistant
Unknown
Total

Susceptible

Intermediately
Susceptible

Resistant

Unknown

Total

95
0
0
0
95

1
0
0
0
I

7
1
0
0
8

0
0
0
18
18

103
1
0
18
122

“Two patients in the levofloxacin group and 3 patients in the comparator
but did not receive study medication.-

listed in Table VIII. All patients in both
treatment groups had significant comorbidity and received study drug for s5 days.
The 3 causative organisms in the levofloxacin group were S pneumoniae (minimum inhibitory concentration [MIC] 1.O
pg/mL) , Staphylococcus aureus (MIC 0.5
FglmL), and H injluenzae (MIC not available). Both organisms with documented
MICs were susceptible to levofloxacin.
The 2 causative organisms in the azithromycin group were H injkenzae (MIC 0.5
pg/mL) and Escherichia coli (MIC 8.0

group were randomized

to treatment

Fg/mL). Because H injluenzae is considered susceptible to azithromycin if its MIC
is 54.0 p,g/mL and E coli is considered
susceptible if its MIC is 52 pg/mL, the
former was susceptible to azithromycin.
None of the cases of pneumococcal bacteremia involved a resistant organism.

Safety Assessment
The safety population consisted of 113
patients in the levofloxacin group and 118
in the azithromycin
group. As seen in
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Table VII. Cross-susceptibility

to levofloxacin

and ceftriaxone

of admission

pathogens.

Ceftriaxone: No. of Isolates
Intermediately
Susceptible

Susceptible
Levofloxacin,* no. of isolates
Susceptible
Intermediately susceptible
Resistant
Unknown
Total

99
1
0
0
100

Resistant

3
0
0
0
3

“Two patients in the levofloxacin group and 3 patients in the comparator
but did not receive study medication.

Unknown

1
0
0
0
1

Treatment/Patient

Comorbidity/
Adverse Event

Levofloxacin
76-year-old woman+ CHF

0
0
0
18
18

group were randomized

Table VIII. Clinical characteristics and minimum inhibitory concentrations
pathogens identified in patients considered treatment failures.

Total

103

1
0
18
122
to treatment

(MICs) of

Duration of
Therapy, d*

Pathogen

3

Streptococcus pneumoniae

L, 1.0
A, 0.12
c, so.25
L, 0.5
A, 1.0
c, 2

MIC,
kLg/mL

39-year-old man+

Empyema

4

Staphylococcus

94-year-old man+*

Multiorgan failure

4

Haemophilus injluenzae

NA

Comparator regimen8
88.year-old man

Respiratory distress

3

H influenzae

L, 0.5
A, 0.5
c, 0.25

Left testicular
necrosis

5

Escherichia coli

L, 8.0
A, 8.0
C, 0.25

62-year-old

man

aureus

CHF = congestive heart failure; L = levofloxacin; A = azithromycin; C = ceftriaxone; NA = not available.
*Number of days before discontinuation of study drug.
tMicrobiologically
evaluable patient in whom causative pathogens were not eradicated.
SPatient died of multiorgan failure after 6 days.
%Jomparator regimen consisted of azithromycin 500 mg IV q24h for 22 days plus ceftriaxone 1 g IV q24h for
2 days, followed by an optional switch to azithromycin 500 mg PO q24h at the investigator’s discretion.
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Table IX. Drug-related

adverse events.
No. (%)
Levofloxacin
(n = 113)

Comparator Regimen*
(n = 118)

6 (5.3)

11 (9.3)
7 (5.9)
5 (4.2)

All body systems
Gastrointestinal disorders
Diarrhea
Nausea
Pseudomembranous
colitis
Vascular disorders
Vein disorders
Skin and appendages
Pruritus
Rash
Sweat gland disorder
Urticaria
Central/peripheral nervous
system disorders
Dizziness
Hypoesthesia
Psychiatric disorders
Insomnia
Paroniria
Body as a whole

0
0
0
0
0
0
3

(0)
(0)
(0)
(0)
(0)
(0)
(2.7)

0 (0)
1 (0.9)
1 (0.9)
1 (0.9)

3
3
2
2

(2.5)
(2.5)
(1.7)
(1.7)

0 (0)
0 (0)
0 (0)

1 (0.9)

1 (0.8)

1 (0.9)

0 (0)
1 (0.8)

0 (0)
2 (1.8)
1 (0.9)
1 (0.9)
1 (0.9)

*Comparator regimen consisted of azithromycin 500 mg IV q24h for r2 days plus ceftriaxone
2 days, followed by an optional switch to azithromycin

Table IX, the overall incidence of drugrelated AEs for all body systems was 5.3%
in the levofloxacin group and 9.3% in the
azithromycin
group. The most common
drug-related
AEs in the azithromycin
group were diarrhea (4.2%), vein disorders (2.5%), and pruritus (1.7%), whereas
no drug-related AE occurred in ~1 .O% of
levofloxacin-treated
patients. One patient
receiving levofloxacin had a serious drugrelated AE, compared with 7 patients receiving azithromycin. Six deaths occurred
during the study: 2 in the levofloxacin

1 (0.8)
1 (0.8)

500 mg PO q24h at the investigator’s

0
0
0
0

(0)
(0)
(0)
(0)

1 g IV q24h for
discretion.

group and 4 in the azithromycin
group.
None of the deaths were considered to be
treatment related.

DISCUSSION
Clinical practice guidelines are important
tools when choosing treatment for a particular disease state. The IDSA guidelines
recommend doxycycline,
macrolides, or
fluoroquinolones
as the preferred antimicrobial agents for the empiric therapy of
most outpatient cases of CAP, and either
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a fluoroquinolone
alone or a beta-lactam/
beta-lactamase
inhibitor
or extendedspectrum cephalosporin combined with a
macrolide for most hospitalized patients
with CAP in general medical wards.9 In
the present trial, levofloxacin monotherapy was at least as effective and well tolerated as traditional combination therapy
with a macrolide and a beta-lactam in the
treatment of moderate to severe CAP. The
pharmacokinetics of levofloxacin are such
that the drug achieves high concentrations
soon after dosing that are sustained at levels far exceeding the MIC required to
achieve 90% inhibition of most respiratory pathogens in both serum and lung
tissue.” Reports sugg est that levofloxacin
is effective in the treatment of pneumococcal CAP (including bacteremic infections)
in patients
who have failed
macrolide therapy, as well as patients with
bacteremic CAP.18,19 Most patients in the
present study had significant disease, as
indicated by a mean Fine risk score of
93.4. They were randomized to once-daily
treatment with levofloxacin IV or PO or
r2 days of combination therapy with azithromycin and ceftriaxone IV, followed
by an optional transition to azithromycin
PO, for a total duration of treatment of
~10 days. The addition of ceftriaxone to
the initial azithromycin regimen was considered a necessary safeguard in patients
with pneumococcal bacteremia. However,
because azithromycin
was not used as
monotherapy, this made it difficult to evaluate the clinical and microbiologic
outcome with azithromycin alone.
The results of this trial suggest that
levofloxacin is at least as effective as azithromycin, despite the fact that azithromycin was initially coadministered
with
ceftriaxone.
Some of the inclusion and
exclusion criteria may have limited the
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ability to extrapolate from the results. The
clinical success rate in clinically evaluable patients was 94.1% in the levofloxacin
group and 92.3% in the azithromycin
group. The respective microbiologic eradication rates were 89.5% and 92.3%. A
strong correlation was observed between
the clinical and microbiologic response in
both treatment groups. Twelve patients in
the levofloxacin group received oral levofloxacin only, and the clinical success rate
in this group was 100%. A total of 5 patients were classified as treatment failures, all of whom had received study
drug for s5 days and all with significant
comorbidity.
Levofloxacin was as well tolerated as
azithromycin,
with an overall incidence
of AEs related to all body systems of 5.3%
and 9.3% of patients, respectively.
The
most common drug-related AEs associated with azithromycin therapy were diarrhea, vein disorders, and pruritus, whereas
no drug-related AE occurred in >I .O% of
levofloxacin-treated
patients. Although 6
deaths occurred during the study, none
were considered treatment related.

CONCLUSIONS
Based on its clinical and microbiologic
efficacy, as well as its favorable tolerability profile, levofloxacin monotherapy appears to be effective in the management
of hospitalized patients with moderate to
severe CAP.

ACKNOWLEDGMENTS
The authors thank the following for their
contributions to this study: Igor Abolnik,
MD, Salt Lake City Veterans Administration Hospital, Salt Lake City, Utah; Kenneth C. Anderson, MD, Baptist East Hos-

E. FRANK ET AL.

pital, Louisville, Kentucky; Marvin J. Bittner, MD, Omaha Veterans Administration
Medical Center, Omaha, Nebraska; Robert
Owen Brennan, MD, Medical Associates
of Central Virginia, Lynchburg, Virginia;
Gary Decker, MD, Infectious Disease Associates, Wilkes-Barre, Pennsylvania;
M.
Pia DeGirolamo, MD, Grandview Hospital, Sellersville,
Pennsylvania;
Elliott
Frank, MD, Jersey Shore Medical Center,
Neptune, New Jersey; Gary Kinasewitz,
MD, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma;
Howard
M. Lazarus,
MD, Harrison
Memorial Hospital, Bremerton, Washington; Jerome F. Levine, MD, Hackensack
University Medical Center, Hackensack,
New Jersey; Diane K. Litwin, MD, St.
Elizabeth
Medical Center, Edgewood,
Kentucky; Jing Liu, MD, Salem Veterans
Affairs Medical Center, Salem, Virginia;
Christopher Lucasti, DO, South Jersey Infectious Disease, Somers Point, New Jersey;
Gregory Moran, MD, Olive View-UCLA
Medical
Center,
Sylmar,
California;
Joseph Plouffe, MD, Ohio State University Medical Center, Columbus, Ohio; Annette Rebouli, MD, Cooper Hospital University Medical Center, Camden, New
Jersey;
Paul Scheinberg,
MD, Saint
Joseph’s Hospital of Atlanta, Atlanta,
Georgia; Leon Smith, MD, St. Michael
Medical Center, Newark, New Jersey; and
Marcus Zervos, MD, William Beaumont
Hospital, Royal Oak, Michigan.

REFERENCES
1. Ginesu F, Pirina P, Deiola G, et al. Etiology and therapy of community-acquired
pneumonia. J Chemother. 1997;9:285-292.
2. Ewig S, Ruiz M, Mensa J, et al. Severe
community-acquired
pneumonia. Assess-

ment of severity criteria. Am J Respir Crit
Care Med. 1998:158:1102-1108.
3. Marrie TJ. Community-acquired
pneumonia: Epidemiology, etiology, treatment. Infect Dis Clin North Am. 1998;12:723-740.
4. Ewig S, Torres A. Severe communityacquired
pneumococcal
pneumoniawhat might be done better. Intensive Cure
Med. 1999;25:143-145.
5. Reynolds
HY. Respiratory
infections:
Community-acquired
pneumonia
and
newer microbes. Lung. 1996;174:207-224.
6. So HY. Severe community-acquired
pneumonia. Anaesth Intensive Care. 1997;25:
222-234.
7. Waterer GW, Somes GW, Wunderink RG.
Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med. 2001;161: 1837-1842.
8. Kahn JB, Wiesinger BA, Drucker LM, et
al. Cumulative clinical trial experience
with levofloxacin in community acquired
pneumonia-associated
pneumococcal bacteremia. Abstract and poster presented at:
The Sixth International Conference on the
Macrolides,
Azalides,
Streptogramins,
Ketolides and Oxazolidinones;
January
23-26,2002; Bologna, Italy. Abstract 8.21.
9. Bartlett JG, Dowel1 SF, Mandell LA, et al,
for the Infectious Diseases Society of
America. Practice guidelines for the management of community-acquired
pneumonia in adults. Clin Infect Dis. 2000;31:
347-382.
10. Lonks JR, Garau J, Gomez L, et al. Failure
of macrolide treatment of erythromycinresistant Streptococcus pneumoniae. Abstract and poster presented at: The Sixth
International Conference on the Macrolides, Azalides, Streptogramins, Ketolides

1307

CLINICAL THERAPEUTICS@

and Oxazolidinones; January 23-26,2002;
Bologna, Italy. Abstract 8.36.
11 Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumonia
due to multidrugresistant pneumococci in 3 patients treated
unsuccessfully with azithromycin and successfully with levofloxacin.
Clin Infect
Dis. 2000;31:613-61.5.

for the difference of two binomial probabilities. Am Statistician. 1986:40:318-322.
16. Guidance for Industry-Draft. Developing
Antimicrobial Drugs-General
Considerations for Clinical Trials. July 1998. Available at: http:liwww.fda.govlcderlguidancei
2580dftpdf. Accessed May 8,2002.

12. Fine MJ, Smith MA, Carson CA, et al.
Prognosis and outcomes of patients with
community-acquired
pneumonia. A metaanalysis. JAMA. 1996;275: 134-141.

17. Gotfried MH, Danziger LH, Rodvold KA.
Steady-state plasma and intrapulmonary
concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest.
2001:119:1114-1122.

13. Levaquin@ prescribing information. Raritan, NJ: Ortho-McNeil
Pharmaceutical;
2002.

18. File TM Jr. Levofloxacin in the treatment
of community acquired pneumonia. Can
Respir J. 1999;6(Suppl A):35A-39A.

14. Zithromax@ prescribing information.
York: Pfizer Inc; 2002.

19. Fogarty CM, Sullivan JG, Chattman MS, et
al. Once a day levofloxacin in the treatment
of mild to moderate and severe communityacquired pneumonia in adults. Infect Dis

New

15. Hauck WW, Anderson S. A comparison of
large-sample confidence interval methods

Clin

B-act.

1998;7:400407.

Address correspondence to: James B. Kahn, MD, Ortho-McNeil
Route 202 South, Raritan, New Jersey 08869-0602.

1308

Pharmaceutical,

1000

